ClinicalTrials.Veeva

Menu
M

Medical Research Partners | Ammon, ID

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3841136
Galcanezumab
LY3549492
Tirzepatide
LY573144
Lasmiditan
LY3305677
LY3298176

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 10 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3549492
Drug: LY3305677

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition...

Enrolling
Weight Gain
Obesity
Drug: Tirzepatide
Drug: Placebo

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: LY3549492

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

Trial sponsors

Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems